19th Hemoglobin Switching Conference

描述(由申请人提供)： 一年两次的血红蛋白转换大会已经持续了37年，其取得巨大成功的原因是多方面的。首先，组织者(Stamatoyannopoulos、Higgs和Engel)总是努力发现并突出新的发现，方法是总是包括影响血红蛋白转换过程的新的研究人员和研究。第三，这些会议在历史上已经演变为关注科学引领的方向，因此仍然非常有针对性，不仅是展示第一个cdna克隆、第一个克隆的人类基因组位置(及其第一个突变)、促红细胞生成素结构的论坛，而且还启动了该领域许多当前领导者的职业生涯(事实上，许多博士后研究员和年轻教师在这次会议上首次在全体会议上展示了他们的工作)。第四，这是唯一一次有关这一话题的会议，来自美国国内外的调查人员出席人数大致相同，这一事实从美国和欧洲之间每两年一次的地点轮换中得到了反映。2014年，该会议将再次在英国牛津牛津大学圣约翰斯学院举行，原因是国际通达性和经济性。

DESCRIPTION (provided by applicant): The biannual Hemoglobin Switching Conference has been ongoing for 37 years, and there are multiple reasons for its resounding success. First and foremost, the organizers (Stamatoyannopoulos, Higgs and Engel) strive to identify and then highlight new discoveries by always including new investigators and studies that impinge on the process of hemoglobin switching. Second, this is the only venue (other than the annual ASH meeting, with more than 14,000 attendees) that brings together basic scientists and clinicians to discuss both the molecular and developmental origins of, and treatments for, hemoglobinopathies. Third, the meetings have historically morphed into focusing on wherever the science led, thus remaining extremely topical, and has not only been the forum for presenting the first cDNA clones, the first cloned human genomic locus (and the first mutations in same), the structure of erythropoietin, but it has also launched the careers of many of the current leaders in this field (indeed, numerous postdoctoral fellows and young faculty first presented their work in plenary sessions at this conference). Fourth, this is the only meeting on this topic that routinely has approximatel equal attendance by investigators from both inside and outside the U.S., and this fact is reflected by the bi-annual alternation in site between the U.S. and Europe. In 2014 the Conference will again be held at St. Johns College at Oxford University in Oxford, England, because of both international accessibility and economy.